

STEP THERAPY CRITERIA

This list is current as of October 1, 2024, and pertains to the following formularies:

2025 Pharmacy Benefit Dimensions PDP offered by Niagara County Formulary – D0122
--

In some cases, we require that you first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B. This document contains the Step Therapy protocols that are associated with the formularies listed above.

If you have any questions, please contact our Medicare Member Services Department at 1-800-667-5936 or, for TTY users 1-800-432-1110, October 1st – March 31st: Monday through Sunday from 8 a.m. to 8 p.m. ET, April 1st – September 30th: Monday through Friday from 8 a.m. to 8 p.m. ET.

Pharmacy Benefit Dimensions is a subsidiary of Independent Health. Independent Health is a PDP with a Medicare contract. Enrollment in Pharmacy Benefit Dimensions PDP depends on contract renewal between Independent Health and CMS.

The formulary may change at any time. You will receive notice when necessary.

Aliskiren Step

Products Affected

- *aliskiren fumarate tablet 150 mg oral*
- *aliskiren fumarate tablet 300 mg oral*

Details

Criteria	Prior prescription history of an ARB to obtain any products containing aliskiren.
----------	---

Eucrisa Step

Products Affected

- EUCRISA OINTMENT 2 % EXTERNAL

Details

Criteria	Prior prescription history positive for the use of either a topical corticosteroid or topical calcineurin inhibitor.
-----------------	--

Hectoral Step Therapy

Products Affected

- *doxercalciferol capsule 0.5 mcg oral*
- *doxercalciferol capsule 1 mcg oral*
- *doxercalciferol capsule 2.5 mcg oral*

Details

Criteria	Prior Prescription history includes past use of calcitriol.
-----------------	---

Pregabalin ER Step

Products Affected

- *pregabalin er tablet extended release 24 hour 165 mg oral*
- *pregabalin er tablet extended release 24 hour 330 mg oral*
- *pregabalin er tablet extended release 24 hour 82.5 mg oral*

Details

Criteria	Requires the use of an immediate-release pregabalin product first.
-----------------	--

Qelbree Step

Products Affected

- QELBREE CAPSULE EXTENDED RELEASE 24 HOUR 100 MG ORAL
- QELBREE CAPSULE EXTENDED RELEASE 24 HOUR 150 MG ORAL
- QELBREE CAPSULE EXTENDED RELEASE 24 HOUR 200 MG ORAL

Details

Criteria	Requires the use of generic atomoxetine first.
-----------------	--

Talicia Step

Products Affected

- TALICIA CAPSULE DELAYED RELEASE 250-12.5-10 MG
ORAL

Details

Criteria	Prior prescription history positive for the use of an empiric (standard first-line) <i>Helicobacter pylori</i> regimen.
-----------------	---

Topical Rosacea Step

Products Affected

- FINACEA FOAM 15 % EXTERNAL

Details

Criteria	Prior prescription history of at least one other topical rosacea medication used for papules/pustules including azelaic acid gel, ivermectin cream, or metronidazole products.
-----------------	--

Uloric Step

Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

Details

Criteria	Requires allopurinol prior to use.
-----------------	------------------------------------

Index

aliskiren fumarate tablet 150 mg oral2
aliskiren fumarate tablet 300 mg oral2
doxercalciferol capsule 0.5 mcg oral 4
doxercalciferol capsule 1 mcg oral 4
doxercalciferol capsule 2.5 mcg oral 4
EUCRISA OINTMENT 2 % EXTERNAL3
febuxostat tablet 40 mg oral9
febuxostat tablet 80 mg oral9
FINACEA FOAM 15 % EXTERNAL 8
pregabalin er tablet extended release 24 hour 165 mg oral 5
pregabalin er tablet extended release 24 hour 330 mg oral 5
pregabalin er tablet extended release 24 hour 82.5 mg oral 5
QELBREE CAPSULE EXTENDED RELEASE 24 HOUR 100 MG ORAL 6
QELBREE CAPSULE EXTENDED RELEASE 24 HOUR 150 MG ORAL 6
QELBREE CAPSULE EXTENDED RELEASE 24 HOUR 200 MG ORAL 6
TALICIA CAPSULE DELAYED RELEASE 250-12.5-10 MG ORAL 7